The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription

Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransfe...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 77; no. 9; pp. 2522 - 2533
Main Authors Wong, Matthew, Tee, Andrew E.L., Milazzo, Giorgio, Bell, Jessica L., Poulos, Rebecca C., Atmadibrata, Bernard, Sun, Yuting, Jing, Duohui, Ho, Nicholas, Ling, Dora, Liu, Pei Yan, Zhang, Xu Dong, Hüttelmaier, Stefan, Wong, Jason W.H., Wang, Jenny, Polly, Patsie, Perini, Giovanni, Scarlett, Christopher J., Liu, Tao
Format Journal Article
LanguageEnglish
Published United States American Association for Cancer Research, Inc 01.05.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR.
AbstractList These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma, a deadly type of pediatric cancer.Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR.
These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma, a deadly type of pediatric cancer. Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene-amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522-33. [copy2017 AACR.
Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes and DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of gene-amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of , and gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc-mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. .
Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of target gene promoters is a strict prerequisite for Myc-induced transcriptional activation, and DOT1L is the only known histone methyltransferase that catalyzes H3K79 methylation. Here, we show that N-Myc upregulates DOT1L mRNA and protein expression by binding to the DOT1L gene promoter. shRNA-mediated depletion of DOT1L reduced mRNA and protein expression of N-Myc target genes ODC1 and E2F2. DOT1L bound to the Myc Box II domain of N-Myc protein, and knockdown of DOT1L reduced histone H3K79 methylation and N-Myc protein binding at the ODC1 and E2F2 gene promoters and reduced neuroblastoma cell proliferation. Treatment with the small-molecule DOT1L inhibitor SGC0946 reduced H3K79 methylation and proliferation of MYCN gene–amplified neuroblastoma cells. In mice xenografts of neuroblastoma cells stably expressing doxycycline-inducible DOT1L shRNA, ablating DOT1L expression with doxycycline significantly reduced ODC1 and E2F2 expression, reduced tumor progression, and improved overall survival. In addition, high levels of DOT1L gene expression in human neuroblastoma tissues correlated with high levels of MYCN, ODC1, and E2F2 gene expression and independently correlated with poor patient survival. Taken together, our results identify DOT1L as a novel cofactor in N-Myc–mediated transcriptional activation of target genes and neuroblastoma oncogenesis. Furthermore, they characterize DOT1L inhibitors as novel anticancer agents against MYCN-amplified neuroblastoma. Cancer Res; 77(9); 2522–33. ©2017 AACR.
Author Milazzo, Giorgio
Perini, Giovanni
Tee, Andrew E.L.
Wong, Matthew
Hüttelmaier, Stefan
Liu, Pei Yan
Scarlett, Christopher J.
Zhang, Xu Dong
Jing, Duohui
Polly, Patsie
Bell, Jessica L.
Poulos, Rebecca C.
Atmadibrata, Bernard
Sun, Yuting
Wong, Jason W.H.
Wang, Jenny
Liu, Tao
Ho, Nicholas
Ling, Dora
Author_xml – sequence: 1
  givenname: Matthew
  surname: Wong
  fullname: Wong, Matthew
– sequence: 2
  givenname: Andrew E.L.
  surname: Tee
  fullname: Tee, Andrew E.L.
– sequence: 3
  givenname: Giorgio
  surname: Milazzo
  fullname: Milazzo, Giorgio
– sequence: 4
  givenname: Jessica L.
  surname: Bell
  fullname: Bell, Jessica L.
– sequence: 5
  givenname: Rebecca C.
  surname: Poulos
  fullname: Poulos, Rebecca C.
– sequence: 6
  givenname: Bernard
  surname: Atmadibrata
  fullname: Atmadibrata, Bernard
– sequence: 7
  givenname: Yuting
  surname: Sun
  fullname: Sun, Yuting
– sequence: 8
  givenname: Duohui
  surname: Jing
  fullname: Jing, Duohui
– sequence: 9
  givenname: Nicholas
  surname: Ho
  fullname: Ho, Nicholas
– sequence: 10
  givenname: Dora
  surname: Ling
  fullname: Ling, Dora
– sequence: 11
  givenname: Pei Yan
  surname: Liu
  fullname: Liu, Pei Yan
– sequence: 12
  givenname: Xu Dong
  surname: Zhang
  fullname: Zhang, Xu Dong
– sequence: 13
  givenname: Stefan
  surname: Hüttelmaier
  fullname: Hüttelmaier, Stefan
– sequence: 14
  givenname: Jason W.H.
  surname: Wong
  fullname: Wong, Jason W.H.
– sequence: 15
  givenname: Jenny
  surname: Wang
  fullname: Wang, Jenny
– sequence: 16
  givenname: Patsie
  surname: Polly
  fullname: Polly, Patsie
– sequence: 17
  givenname: Giovanni
  surname: Perini
  fullname: Perini, Giovanni
– sequence: 18
  givenname: Christopher J.
  surname: Scarlett
  fullname: Scarlett, Christopher J.
– sequence: 19
  givenname: Tao
  surname: Liu
  fullname: Liu, Tao
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28209620$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1LwzAYxoMouk3_BKXgxUtn0iZNiieZugnzA5knDyFN32qlbWaSHvbfm7LpwYMQeAn8nuf9eMZovzMdIHRK8JQQJi4xxiJmlCfT2fVjTLLwsnQPjQhLRcwpZfto9MscobFzn-HLCGaH6CgRCc6zBI_Q2-oDokXtfHCPHsB_bBpvVecqsMpBdPO0Isvo2ZrWeHDRI_TWFI0KeKuiYhO9wHvfKF9379EcgsNq0Gpbr31tumN0UKnGwcmuTtDr3e1qtoiXT_P72fUy1lSkPuZFkXGAiiWcYU5ZGsYsy0IoUYqCsrxMGaGCFGWaZZjnmrMkgVxrzXJVVoqmE3Sx9V1b89WD87KtnYamUR2Y3kmSY8JpTigO6Pkf9NP0tgvTBUqkCcOYk0Cd7ai-aKGUa1u3ym7kz9kCcLUFtDXOWaikrr0adg7HqxtJsBxCkkMAcghAhpAkyeQQUlCzP-qfBv_rvgEjEZQc
CitedBy_id crossref_primary_10_1016_j_bbcan_2022_188805
crossref_primary_10_18632_oncotarget_26416
crossref_primary_10_1007_s10555_020_09946_y
crossref_primary_10_1089_omi_2018_0206
crossref_primary_10_3390_diseases9040078
crossref_primary_10_3390_ijms20010131
crossref_primary_10_1007_s00441_017_2773_y
crossref_primary_10_3389_fonc_2019_01361
crossref_primary_10_1016_j_molcel_2019_06_034
crossref_primary_10_1002_cam4_70082
crossref_primary_10_1158_0008_5472_CAN_24_3304
crossref_primary_10_3389_fendo_2023_1085605
crossref_primary_10_1002_ijc_32936
crossref_primary_10_1126_sciadv_aav5590
crossref_primary_10_1016_j_jpha_2022_11_008
crossref_primary_10_1016_j_celrep_2021_109739
crossref_primary_10_1155_2021_6612689
crossref_primary_10_1038_s41467_019_12971_3
crossref_primary_10_1016_j_it_2021_03_006
crossref_primary_10_1038_s41423_018_0170_4
crossref_primary_10_18632_oncotarget_25084
crossref_primary_10_1126_scitranslmed_aao4680
crossref_primary_10_1016_j_canlet_2024_217263
crossref_primary_10_1007_s40495_018_0130_9
crossref_primary_10_2485_jhtb_31_101
crossref_primary_10_1158_1078_0432_CCR_21_1299
crossref_primary_10_1186_s13148_019_0778_y
crossref_primary_10_1016_j_bbagrm_2022_194840
crossref_primary_10_1038_s41392_020_00323_3
crossref_primary_10_1038_s41419_019_2201_1
crossref_primary_10_1038_s41467_019_11132_w
crossref_primary_10_1158_2159_8290_CD_21_0646
crossref_primary_10_1002_hep_31141
crossref_primary_10_1038_s41467_020_18013_7
crossref_primary_10_1186_s13058_022_01547_7
crossref_primary_10_3390_ijms242317085
crossref_primary_10_1073_pnas_1920372117
crossref_primary_10_1002_cnr2_2150
crossref_primary_10_1261_rna_070292_119
crossref_primary_10_3390_biom13010061
crossref_primary_10_1039_D1CB00016K
crossref_primary_10_1111_jcmm_13644
crossref_primary_10_15252_embr_202051184
crossref_primary_10_1038_s41392_024_02039_0
crossref_primary_10_3389_fcell_2021_727353
crossref_primary_10_1038_s41388_022_02428_1
crossref_primary_10_2174_0113816128272203231121034814
crossref_primary_10_1186_s12964_024_01895_1
Cites_doi 10.1016/S0960-9822(02)00901-6
10.1016/0959-8049(95)00015-B
10.1016/j.ejca.2009.03.002
10.1038/nrc1014
10.1016/j.cell.2007.05.009
10.1158/1078-0432.CCR-15-1666
10.1182/blood-2013-04-497644
10.1101/gad.2057811
10.1038/tpj.2010.53
10.1083/jcb.108.3.1093
10.1371/journal.pone.0003650
10.1093/hmg/10.7.699
10.1038/nature10910
10.1038/sj.onc.1208699
10.1093/emboj/19.21.5813
10.1200/JCO.1999.17.7.2264
10.1101/gad.1198204
10.1093/jnci/dju113
10.1083/jcb.107.4.1325
10.1182/blood-2011-02-334359
10.1038/sj.onc.1210661
10.1038/ncomms8821
10.1073/pnas.0806213105
10.1016/S1097-2765(01)00275-1
10.1200/JCO.2008.16.0630
10.1056/NEJMra0804577
10.1158/0008-5472.CAN-07-6866
10.1016/j.molcel.2015.02.028
10.1038/ncb1434
10.1158/0008-5472.CAN-10-2386
10.1038/nm.3832
10.1101/gad.1712408
10.1038/cddis.2013.84
10.1038/ncomms2304
10.1158/0008-5472.CAN-15-0423
10.1016/S0092-8674(03)00114-4
10.1016/j.ccr.2011.06.009
10.1038/nature10953
10.1007/978-1-4612-4380-9_25
10.1016/j.molcel.2005.05.009
ContentType Journal Article
Copyright 2017 American Association for Cancer Research.
Copyright American Association for Cancer Research, Inc. May 1, 2017
Copyright_xml – notice: 2017 American Association for Cancer Research.
– notice: Copyright American Association for Cancer Research, Inc. May 1, 2017
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7TM
7TO
7U9
8FD
FR3
H94
P64
RC3
DOI 10.1158/0008-5472.CAN-16-1663
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList Genetics Abstracts
Genetics Abstracts
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1538-7445
EndPage 2533
ExternalDocumentID 28209620
10_1158_0008_5472_CAN_16_1663
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-ET
18M
29B
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AETEA
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CITATION
CS3
DIK
DU5
EBS
EJD
F5P
FRP
GX1
H13
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
PQQKQ
RCR
RHI
RNS
SJN
TR2
W2D
W8F
WH7
WOQ
YKV
YZZ
CGR
CUY
CVF
ECM
EIF
NPM
RHF
7T5
7TM
7TO
7U9
8FD
FR3
H94
P64
RC3
ID FETCH-LOGICAL-c483t-7bb67eef527507453005ddb8a8d8b459d351481bd366079c7522e9ccc59adfa43
ISSN 0008-5472
IngestDate Mon Jul 21 11:06:16 EDT 2025
Fri Jul 25 19:59:50 EDT 2025
Wed Feb 19 02:40:22 EST 2025
Thu Apr 24 22:58:22 EDT 2025
Tue Jul 01 01:12:29 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
License 2017 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c483t-7bb67eef527507453005ddb8a8d8b459d351481bd366079c7522e9ccc59adfa43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://cancerres.aacrjournals.org/content/canres/77/9/2522.full.pdf
PMID 28209620
PQID 1983250071
PQPubID 105549
PageCount 12
ParticipantIDs proquest_miscellaneous_1901749140
proquest_journals_1983250071
pubmed_primary_28209620
crossref_citationtrail_10_1158_0008_5472_CAN_16_1663
crossref_primary_10_1158_0008_5472_CAN_16_1663
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-05-01
PublicationDateYYYYMMDD 2017-05-01
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Baltimore
PublicationTitle Cancer research (Chicago, Ill.)
PublicationTitleAlternate Cancer Res
PublicationYear 2017
Publisher American Association for Cancer Research, Inc
Publisher_xml – name: American Association for Cancer Research, Inc
References Nguyen (2022061706165727000_bib29) 2011; 25
Brodeur (2022061706165727000_bib1) 2003; 3
Martinato (2022061706165727000_bib11) 2008; 3
Eilers (2022061706165727000_bib9) 2008; 22
Molenaar (2022061706165727000_bib23) 2012; 483
Nevins (2022061706165727000_bib39) 2001; 10
Yu (2022061706165727000_bib35) 2012; 3
Barski (2022061706165727000_bib14) 2007; 129
Schubeler (2022061706165727000_bib16) 2004; 18
Thomas (2022061706165727000_bib37) 2015; 58
Liu (2022061706165727000_bib20) 2009; 45
Onder (2022061706165727000_bib22) 2012; 483
Shahbazi (2022061706165727000_bib19) 2016; 22
Chen (2022061706165727000_bib28) 2015; 21
Min (2022061706165727000_bib13) 2003; 112
Herold (2022061706165727000_bib21) 2008; 105
Oberthuer (2022061706165727000_bib25) 2010; 10
Beier (2022061706165727000_bib30) 2000; 19
Daigle (2022061706165727000_bib34) 2011; 20
Cho (2022061706165727000_bib38) 2015; 6
Kaplan (2022061706165727000_bib26) 1992
Matthay (2022061706165727000_bib2) 1995; 31a
Feng (2022061706165727000_bib12) 2002; 12
Hogarty (2022061706165727000_bib31) 2008; 68
Hirvonen (2022061706165727000_bib7) 1989; 108
Leone (2022061706165727000_bib32) 2001; 8
Mugrauer (2022061706165727000_bib6) 1988; 107
Nguyen (2022061706165727000_bib17) 2011; 117
Daigle (2022061706165727000_bib33) 2013; 122
Janoueix-Lerosey (2022061706165727000_bib3) 2009; 27
Fujiwara (2022061706165727000_bib40) 2011; 71
Guccione (2022061706165727000_bib10) 2006; 8
Kocak (2022061706165727000_bib24) 2013; 4
Tomioka (2022061706165727000_bib5) 2008; 27
Morillon (2022061706165727000_bib15) 2005; 18
Zeisig (2022061706165727000_bib18) 2005; 24
Maris (2022061706165727000_bib4) 2010; 362
Maris (2022061706165727000_bib8) 1999; 17
Liu (2022061706165727000_bib27) 2014; 106
Sun (2022061706165727000_bib36) 2015; 75
References_xml – volume: 12
  start-page: 1052
  year: 2002
  ident: 2022061706165727000_bib12
  article-title: Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain
  publication-title: Curr Biol
  doi: 10.1016/S0960-9822(02)00901-6
– volume: 31a
  start-page: 572
  year: 1995
  ident: 2022061706165727000_bib2
  article-title: Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results
  publication-title: Eur J Cancer
  doi: 10.1016/0959-8049(95)00015-B
– volume: 45
  start-page: 1846
  year: 2009
  ident: 2022061706165727000_bib20
  article-title: Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2009.03.002
– volume: 3
  start-page: 203
  year: 2003
  ident: 2022061706165727000_bib1
  article-title: Neuroblastoma: biological insights into a clinical enigma
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1014
– volume: 129
  start-page: 823
  year: 2007
  ident: 2022061706165727000_bib14
  article-title: High-resolution profiling of histone methylations in the human genome
  publication-title: Cell
  doi: 10.1016/j.cell.2007.05.009
– volume: 22
  start-page: 2534
  year: 2016
  ident: 2022061706165727000_bib19
  article-title: The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat synergistically reduce N-Myc expression and induce anticancer effects
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-1666
– volume: 122
  start-page: 1017
  year: 2013
  ident: 2022061706165727000_bib33
  article-title: Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
  publication-title: Blood
  doi: 10.1182/blood-2013-04-497644
– volume: 25
  start-page: 1345
  year: 2011
  ident: 2022061706165727000_bib29
  article-title: The diverse functions of Dot1 and H3K79 methylation
  publication-title: Genes Dev
  doi: 10.1101/gad.2057811
– volume: 10
  start-page: 258
  year: 2010
  ident: 2022061706165727000_bib25
  article-title: Comparison of performance of one-color and two-color gene-expression analyses in predicting clinical endpoints of neuroblastoma patients
  publication-title: Pharmacogenomics J
  doi: 10.1038/tpj.2010.53
– volume: 108
  start-page: 1093
  year: 1989
  ident: 2022061706165727000_bib7
  article-title: The N-myc proto-oncogene and IGF-II growth factor mRNAs are expressed by distinct cells in human fetal kidney and brain
  publication-title: J Cell Biol
  doi: 10.1083/jcb.108.3.1093
– volume: 3
  start-page: e3650
  year: 2008
  ident: 2022061706165727000_bib11
  article-title: Analysis of Myc-induced histone modifications on target chromatin
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0003650
– volume: 10
  start-page: 699
  year: 2001
  ident: 2022061706165727000_bib39
  article-title: The Rb/E2F pathway and cancer
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/10.7.699
– volume: 483
  start-page: 589
  year: 2012
  ident: 2022061706165727000_bib23
  article-title: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
  publication-title: Nature
  doi: 10.1038/nature10910
– volume: 24
  start-page: 5525
  year: 2005
  ident: 2022061706165727000_bib18
  article-title: The eleven-nineteen-leukemia protein ENL connects nuclear MLL fusion partners with chromatin
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1208699
– volume: 19
  start-page: 5813
  year: 2000
  ident: 2022061706165727000_bib30
  article-title: Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events
  publication-title: EMBO J
  doi: 10.1093/emboj/19.21.5813
– volume: 17
  start-page: 2264
  year: 1999
  ident: 2022061706165727000_bib8
  article-title: Molecular biology of neuroblastoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.1999.17.7.2264
– volume: 18
  start-page: 1263
  year: 2004
  ident: 2022061706165727000_bib16
  article-title: The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote
  publication-title: Genes Dev
  doi: 10.1101/gad.1198204
– volume: 106
  start-page: dju113
  year: 2014
  ident: 2022061706165727000_bib27
  article-title: Effects of a novel long noncoding RNA, lncUSMycN, on N-Myc expression and neuroblastoma progression
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju113
– volume: 107
  start-page: 1325
  year: 1988
  ident: 2022061706165727000_bib6
  article-title: N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization
  publication-title: J Cell Biol
  doi: 10.1083/jcb.107.4.1325
– volume: 117
  start-page: 6912
  year: 2011
  ident: 2022061706165727000_bib17
  article-title: DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis
  publication-title: Blood
  doi: 10.1182/blood-2011-02-334359
– volume: 27
  start-page: 441
  year: 2008
  ident: 2022061706165727000_bib5
  article-title: Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1210661
– volume: 6
  start-page: 7821
  year: 2015
  ident: 2022061706165727000_bib38
  article-title: DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression
  publication-title: Nat Commun
  doi: 10.1038/ncomms8821
– volume: 105
  start-page: 18507
  year: 2008
  ident: 2022061706165727000_bib21
  article-title: Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0806213105
– volume: 8
  start-page: 105
  year: 2001
  ident: 2022061706165727000_bib32
  article-title: Myc requires distinct E2F activities to induce S phase and apoptosis
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(01)00275-1
– volume: 27
  start-page: 1026
  year: 2009
  ident: 2022061706165727000_bib3
  article-title: Overall genomic pattern is a predictor of outcome in neuroblastoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.16.0630
– volume: 362
  start-page: 2202
  year: 2010
  ident: 2022061706165727000_bib4
  article-title: Recent advances in neuroblastoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0804577
– volume: 68
  start-page: 9735
  year: 2008
  ident: 2022061706165727000_bib31
  article-title: ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-07-6866
– volume: 58
  start-page: 440
  year: 2015
  ident: 2022061706165727000_bib37
  article-title: Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2015.02.028
– volume: 8
  start-page: 764
  year: 2006
  ident: 2022061706165727000_bib10
  article-title: Myc-binding-site recognition in the human genome is determined by chromatin context
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1434
– volume: 71
  start-page: 1924
  year: 2011
  ident: 2022061706165727000_bib40
  article-title: Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-10-2386
– volume: 21
  start-page: 335
  year: 2015
  ident: 2022061706165727000_bib28
  article-title: DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
  publication-title: Nat Med
  doi: 10.1038/nm.3832
– volume: 22
  start-page: 2755
  year: 2008
  ident: 2022061706165727000_bib9
  article-title: Myc's broad reach
  publication-title: Genes Dev
  doi: 10.1101/gad.1712408
– volume: 4
  start-page: e586
  year: 2013
  ident: 2022061706165727000_bib24
  article-title: Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2013.84
– volume: 3
  start-page: 1288
  year: 2012
  ident: 2022061706165727000_bib35
  article-title: Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
  publication-title: Nat Commun
  doi: 10.1038/ncomms2304
– volume: 75
  start-page: 5143
  year: 2015
  ident: 2022061706165727000_bib36
  article-title: WDR5 supports an N-Myc transcriptional complex that drives a protumorigenic gene expression signature in neuroblastoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-15-0423
– volume: 112
  start-page: 711
  year: 2003
  ident: 2022061706165727000_bib13
  article-title: Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase
  publication-title: Cell
  doi: 10.1016/S0092-8674(03)00114-4
– volume: 20
  start-page: 53
  year: 2011
  ident: 2022061706165727000_bib34
  article-title: Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.06.009
– volume: 483
  start-page: 598
  year: 2012
  ident: 2022061706165727000_bib22
  article-title: Chromatin-modifying enzymes as modulators of reprogramming
  publication-title: Nature
  doi: 10.1038/nature10953
– start-page: 319
  volume-title: Breakthroughs in Statistics.
  year: 1992
  ident: 2022061706165727000_bib26
  article-title: Nonparametric estimation from incomplete observations
  doi: 10.1007/978-1-4612-4380-9_25
– volume: 18
  start-page: 723
  year: 2005
  ident: 2022061706165727000_bib15
  article-title: Dynamic lysine methylation on histone H3 defines the regulatory phase of gene transcription
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2005.05.009
SSID ssj0005105
Score 2.4821823
Snippet Myc oncoproteins exert tumorigenic effects by regulating expression of target oncogenes. Histone H3 lysine 79 (H3K79) methylation at Myc-responsive elements of...
These findings offer a preclinical proof of concept for the use of DOT1L inhibitors as a strategy to disrupt the function of amplified N-MYC in neuroblastoma,...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 2522
SubjectTerms Animals
Antitumor agents
Cancer
Cell Line, Tumor
Cell proliferation
Cell Proliferation - drug effects
DNA methylation
DNA Methylation - drug effects
Doxycycline
Enzyme Inhibitors - administration & dosage
Gene expression
Gene Expression Regulation, Neoplastic - drug effects
Histone H3
Histone methyltransferase
Histone-Lysine N-Methyltransferase - antagonists & inhibitors
Histone-Lysine N-Methyltransferase - genetics
Humans
Lysine
Methyltransferases - antagonists & inhibitors
Methyltransferases - genetics
Mice
Myc protein
MYCN gene
N-Myc protein
N-Myc Proto-Oncogene Protein - biosynthesis
N-Myc Proto-Oncogene Protein - genetics
Neuroblastoma
Neuroblastoma - drug therapy
Neuroblastoma - genetics
Neuroblastoma - pathology
Neuroblasts
Promoter Regions, Genetic
Promoters
Protein expression
Proteins
Transcription activation
Transcription, Genetic
Tumorigenesis
Xenografts
Title The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
URI https://www.ncbi.nlm.nih.gov/pubmed/28209620
https://www.proquest.com/docview/1983250071
https://www.proquest.com/docview/1901749140
Volume 77
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSIgXxDcdAxmJtyolH3YSP06lYxptJ1AqVeIhih0HJoUOdekD_eu5s5200YYYSFVUpbFd-X45n8-_uyPknR9WHJYx7YlIKo-lvvJkgn6rUpew4OLRHMYOz-bx6YKdLflyRwky0SWNHKntjXEl_yNVuAdyxSjZf5Bs1yncgO8gX7iChOF6axmbPB9gKc40THndGDtUr2FtGn44z4IpRgKANDSqsw0Wjyng8R8FWp1fbBl644ECjWfznLdKZN9oHSMy1kOXF-i7Ofi1DA6jYep6tOdPaDm-rpB45xmwhB_LnxxOOpfz7KIutlvT0ceLy_U3Swvbjxw6Q6KuKlx4hHNQwKLX0QE7pZt6nCU9petqt1hwiX0Nym2csluNQ27zZFzX9Dy11Ejb92h8PPeCGD5OX_Yya8_P85PFdJpnk2V2l9wLYUuB1S4-fd5llueO7tp26KK9YJj3Nw7St2P-sDkxRkr2iDx0uwt6bKHymNzRqyfk_szxJ56Sr4AY6hBDryGGGsTQFjG0hxgqf9EdYigihvYQ84wsTibZ-NRz5TU8xdKo8RIp40TrimOK_4RxLFxQljIt0jKVjIsSgzxgV1NGcewnQiUgGS2UUlwUZVWw6Dk5WMHffUkomD8yjDRXItSsiispZFQynUSxKBRIcEBYO1m5crnnsQRKnZs9KE-RA5HmOMc5zHEexDnO8YCMumY_bfKVvzU4aiWRu_f0Kg8ErFocbekBedv9DFoUj8aKlb7c4DMAXCYC5g_ICyvBbsQQjGQRh_7hLVq_Ig92r8AROWjWG_0arNZGvjFw-w3L2pIW
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Histone+Methyltransferase+DOT1L+Promotes+Neuroblastoma+by+Regulating+Gene+Transcription&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Wong%2C+Matthew&rft.au=Tee%2C+Andrew+EL&rft.au=Milazzo%2C+Giorgio&rft.au=Bell%2C+Jessica+L&rft.date=2017-05-01&rft.issn=0008-5472&rft.volume=77&rft.issue=9&rft.spage=2522&rft.epage=2533&rft_id=info:doi/10.1158%2F0008-5472.CAN-16-1663&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon